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A B S T R A C T
Background
COVID-19 infection poses a serious risk to patients and – due to its contagious nature – to those healthcare workers (HCWs) treating them.
The risks of transmission of infection are greater when a patient is undergoing an aerosol-generating procedure (AGP). Not all those with
COVID-19 infection are symptomatic, or suspected of harbouring the infection. If a patient who is not known to have or suspected of having
COVID-19 infection is to undergo an AGP, it would nonetheless be sensible to minimise the risk to those HCWs treating them.
If the mouth and nose of an individual undergoing an AGP are irrigated with antimicrobial solutions, this may be a simple and safe method
of reducing the risk of any covert infection being passed to HCWs through droplet transmission or direct contact. Alternatively, the use of
antimicrobial solutions by the HCW may decrease the chance of them acquiring COVID-19 infection. However, the use of such antimicrobial
solutions may be associated with harms related to the toxicity of the solutions themselves or alterations in the natural microbial flora of
the mouth or nose.
Objectives
To assess the benefits and harms of antimicrobial mouthwashes and nasal sprays administered to HCWs and/or patients when undertaking
AGPs on patients without suspected or confirmed COVID-19 infection.
Search methods
Information Specialists from Cochrane ENT and Cochrane Oral Health searched the Central Register of Controlled Trials (CENTRAL 2020,
Issue 6); Ovid MEDLINE; Ovid Embase and additional sources for published and unpublished trials. The date of the search was 1 June 2020.
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Selection criteria
This is a question that urgently requires evidence, however at the present time we did not anticipate finding many completed RCTs. We
therefore planned to include the following types of studies: randomised controlled trials (RCTs); quasi-RCTs; non-randomised controlled
trials; prospective cohort studies;  retrospective cohort studies;  cross-sectional studies;  controlled before-and-aKer studies. We set no
minimum duration for the studies. 
We sought studies comparing any antimicrobial mouthwash and/or nasal spray (alone or in combination) at any concentration, delivered
to the patient or HCW before and/or aKer an AGP.
Data collection and analysis
We used standard Cochrane methodological procedures. Our primary outcomes were: 1) incidence of symptomatic or test-positive
COVID-19 infection in HCWs or patients; 2) significant adverse event: anosmia (or disturbance in sense of smell). Our secondary outcomes
were: 3) COVID-19 viral content of aerosol (when present); 4) change in COVID-19 viral load at site(s) of irrigation; 5) other adverse events:
changes in microbiome in oral cavity, nasal cavity, oro- or nasopharynx; 6) other adverse events: allergy, irritation/burning of nasal, oral
or oropharyngeal mucosa (e.g. erosions, ulcers, bleeding), long-term staining of mucous membranes or teeth, accidental ingestion. We
planned to use GRADE to assess the certainty of the evidence for each outcome.
Main results
We found no completed studies to include in this review. 
Authors' conclusions
We identified no studies for inclusion in this review, nor any ongoing studies. The absence of completed studies is not surprising given
the relatively recent emergence of COVID-19 infection. However, we are disappointed that this important clinical question is not being
addressed by ongoing studies.
P L A I N   L A N G U A G E   S U M M A R Y
Does the use of antimicrobial mouthwash or nasal spray by people who are not actively suspected of having COVID-19 - or by their
healthcare workers - protect their healthcare workers when they undertake 'aerosol-generating procedures' on them?
Why is this question important?
COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Most people infected with COVID-19 develop a mild to moderate
respiratory illness, and some may have no symptoms (asymptomatic infection). Others experience severe symptoms and need specialist
treatment and intensive care.
COVID-19 spreads from person to person primarily through droplets that are produced when an infected person coughs, sneezes or talks.
A person can also become infected by touching a surface or object that has viral droplets on it, and then touching their own mouth or nose.
Some people with COVID-19 do not have any symptoms, therefore they might not be known to be or suspected of being infected. However,
they might still be able to pass the infection on to others. This means that healthcare workers who are treating them may be at risk of
catching the infection. Risk of infection may be particularly high when healthcare workers undertake 'aerosol-generating procedures',
which are medical procedures that cause the patient to produce many small droplets. For example, people who have surgery under general
anaesthesia, or people with a lung disease that makes breathing diFicult (such as pneumonia), may need to be placed on a ventilator
(artificial breathing machine) to help them breathe. This requires a healthcare worker to insert a tube through the patient's mouth, into
their airway – a procedure during which many small droplets are likely to be produced by the patient. Similar droplets can be produced
during routine dental procedures, such as drilling or scaling of teeth.
Patient or healthcare worker use of antimicrobial mouthwash (to rinse the mouth) or nasal spray (sprayed into the nose) might help to
protect healthcare workers against infection by COVID-19. Antimicrobial mouthwash and nasal spray are liquids that kill or stop the growth
of micro-organisms such as viruses or bacteria.
As with any medical treatment, antimicrobial mouthwash and nasal spray have potential risks as well as benefits. It is possible that using
mouthwash or nasal spray could cause a variety of unwanted (adverse) eFects, including irritation, allergic reactions or loss of smell. It
may also remove micro-organisms from the mouth or nose that are useful for protecting the body against infection.
We set out to assess the benefits and risks of self-administration of antimicrobial mouthwashes and nasal sprays by patients without a
known or suspected COVID-19 infection, or the healthcare workers who treat them with aerosol-generating procedures, by reviewing the
research evidence.
How did we search for evidence?
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Our team of researchers searched the medical literature for studies that compared the eFects of patients or healthcare workers self-
administering any antimicrobial mouthwash or nasal spray against using no treatment, water or a salt solution.
What did we find?
We found no completed, or ongoing, studies to include in this review.
What does this mean?
There is currently no evidence relating to the benefits and risks of healthcare workers' or patients' use of antimicrobial mouthwashes
or nasal sprays to protect healthcare workers who undertake aerosol-generating procedures on patients without a known or suspected
COVID-19 infection.
We need studies to be conducted so that we can answer this important clinical question.
How-up-to date is this review?
We last searched for evidence on 1 June 2020. This review covered research that was available up to that date, but did not consider any
evidence that may have been produced since then.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Antimicrobial mouthwashes (gargling) and nasal sprays to protect healthcare workers when undertaking aerosol-generating
procedures (AGPs) on patients without suspected or confirmed COVID-19 infection
Antimicrobial mouthwashes (gargling) and nasal sprays to protect healthcare workers when undertaking aerosol-generating procedures (AGPs) on patients without sus-
pected or confirmed COVID-19 infection
Patient or population: patients without suspected or confirmed COVID-19 infection, undergoing aerosol-generating procedures (AGPs) and those healthcare workers
(HCWs) treating them
Setting: any healthcare setting
Intervention: any antimicrobial mouthwash and/or nasal spray
Comparison: no treatment or saline or water
Anticipated absolute effects* (95% CI)Outcomes Relative ef-
fect












Incidence of symptomatic or test-positive COVID-19 infection in
HCWs or patients
No data available (no included studies)
Anosmia No data available (no included studies)
COVID-19 viral content of aerosol No data available (no included studies)
Change in COVID-19 viral load at site(s) of irrigation No data available (no included studies)
Changes in microbiome in oral cavity, nasal cavity, oro-or na-
sopharynx
No data available (no included studies)
Other adverse events No data available (no included studies)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; RR: risk ratio; OR: odds ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
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B A C K G R O U N D
Description of the condition
The emergence of a novel coronavirus (SARS-CoV-2) in late 2019
has resulted in a global pandemic of an infectious condition -
COVID-19. To date, almost 19.9 million people have been reported
to be infected, with close to 732,000 deaths. Patients may be
asymptomatic, or they may have an illness with symptoms varying
from mild to very severe. Not all those who have the condition
are tested for the presence of the virus. Multiple therapeutic
interventions and vaccines are in development. The steroid
dexamethasone has been shown to reduce the mortality rate of
people requiring invasive ventilation for COVID-19 by a third (Horby
2020), and the antiviral drug remdesivir can reduce the time to
recovery of patients in hospital (Beigel 2020). Prevention eForts
have focused on measures of social distancing and isolation in
many countries.
Healthcare workers are at the forefront of this crisis, with repeated
exposure to individuals who are, or may be, infected, and are
therefore at risk themselves. Access to and proper use of personal
protective equipment (PPE) is a key intervention that should
reduce the frequency of transmission of the infection to healthcare
workers.
These workers may be especially at risk when undertaking 'aerosol-
generating procedures' (AGPs). This is any medical, dental or
patient-care procedure that results in the production of airborne
particles (aerosols) from the upper aerodigestive tract (mouth,
nose, throat, oesophagus) and lower respiratory tract where the
virus is shedding. These can remain suspended in the air and travel
over a distance. They may cause infection if they are inhaled. Such
procedures therefore create the potential for airborne transmission
of infection.
This review is one of a set of three which consider two measures
that may protect healthcare workers and patients - both for their
own benefit, and to reduce the frequency of onward transmission.
These two measures are 1) the pre-procedural use of mouthwashes
and nasal sprays by patients, to reduce the risk that any aerosol
that they generate will infect healthcare workers, and 2) the use
of mouthwashes and nasal sprays by healthcare workers pre- and
post-exposure to patients with confirmed or suspected infection
to reduce the risk of acquiring such infection through their mouth
or nose. This particular review focuses on the protection of HCWs
when they are undertaking AGPs on patients who are not known
to have, or suspected of having, COVID-19 infection. It evaluates
the use of mouthwashes and nasal sprays by either the patients (1)
above) or the HCWs treating them (2) above) or both. (The other two
reviews will focus on a) the use of antimicrobial mouthwashes and
nasal sprays by HCWs treating patients with suspected or confirmed
COVID-19 infection (Burton 2020a) and b) the use of antimicrobial
mouthwashes and nasal sprays by patients with suspected or
confirmed COVID-19 infection (Burton 2020b)).
Description of the intervention
Mouthwashes are oral rinsing solutions: many are in common
use to manage halitosis, prevent tooth decay and reduce plaque
formation. In some countries they are recommended as a
hygiene measure during the regular cold and flu season. Many
mouthwashes with some antimicrobial activity can be purchased
over the counter, and others are available on prescription. The
antimicrobial agents and eFectiveness vary and whilst most have
some antibacterial properties a few are also antiviral.
Similar topical antimicrobial solutions may be administered via
the nose using a nasal spray, or by direct irrigation or douching
(administered by sniFing a solution through each nostril and
spitting it out).
How the intervention might work
There has been considerable interest in the use of nasal irrigation
or oral rinses to prevent transmission of upper respiratory tract
infections (URTI) caused by viruses, or to alleviate their symptoms.
Transmission of such disease occurs by the inhalation of small
droplets containing viral particles, or by transfer (for example,
from surfaces to hands, and then to the face, mouth and nose).
Rinsing the mouth and/or nose may eradicate viral particles
completely - preventing transmission to that individual - or reduce
the viral load that the individual is exposed to. This may prevent
the disease developing in that individual or reduce the severity
of it. Gargles that have been investigated for their ability to
reduce viral transmission include tea (or components of tea) (Ide
2016), water (Goodall 2014) and povidone iodine (Kitamura 2007;
Satomura 2005). Other mouthwashes in common use, including
hydrogen peroxide and chlorhexidine, may also have antiviral
activity (Bernstein 1990).
Nasal irrigation with topical antimicrobial solutions similar to those
used as mouthwashes has also been investigated. Carrageenan, a
carbohydrate found in red seaweed, has been trialled as an antiviral
nasal spray. Studies have identified a decrease in the nasal viral
load from URTI, but results on symptomatic improvement have
been mixed (Eccles 2010; Eccles 2015; Fazekas 2012; Ludwig 2013).
Given the new emergence of COVID-19, the eFicacy of nasal or oral
irrigation fluids against this disease is not yet known. However,
activity against similar novel coronaviruses (such as those
responsible for severe acute respiratory syndrome (SARS) and
Middle East respiratory syndrome (MERS)) has been demonstrated
for some preparations (Eggers 2015; Kariwa 2006). Gargle solutions
of povidone iodine have been shown to be active against the
coronaviruses causing both MERS and SARS in vitro (Eggers 2018;
Kariwa 2006).
How the intervention might cause harm
Use of mouthwash or nasal irrigation has the potential to cause a
variety of adverse eFects. In common with many treatments, there
is the possibility of irritation or allergic reaction to components of
the product. A key concern for any agent used intranasally is the
potential for long-term damage resulting in anosmia (loss of sense
of smell). However, anosmia may also be a symptom of COVID-19
infection.
There is also a concern that local application of antimicrobials
will disrupt the normal nasal and oral microbiota. The microbiome
is increasingly recognised as playing a vital role in preventing
colonisation with invading pathogens, supporting the host immune
system and a variety of other functions (Kilian 2016; Man
2017). Alteration of this delicate environment by exposure to
antimicrobial compounds could alter the composition and/or
activities  of the oral and nasal microbiotas. This may occur
through reduced total microbial abundance and/or via the selective
Antimicrobial mouthwashes (gargling) and nasal sprays to protect healthcare workers when undertaking aerosol-generating procedures
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suppression of commensal micro-organisms with the greatest
susceptibility to the treatment. Potential health problems resulting
from this include an increased risk of infection due to the
suppression of colonisation resistance, by which commensal
micro-organisms inhibit extrinsic pathogens, the overgrowth of
species within the microbiota with pathogenic potential, and
interference with beneficial host-microbe interactions that prime
the immune system.
Other potential harms are related to specific irrigation fluids. These
include the risk of excess iodine ingestion from iodine-containing
gargle solution or staining of teeth with chlorhexidine.
O B J E C T I V E S
To assess the benefits and harms of antimicrobial mouthwashes
and nasal sprays administered to healthcare workers (HCWs)
and/or patients when undertaking aerosol-generating procedures
(AGPs) on patients without suspected or confirmed COVID-19
infection.
M E T H O D S
Criteria for considering studies for this review
Types of studies
This is a question that urgently requires evidence, however at the
present time we did not anticipate finding many completed RCTs.
We therefore included the following types of studies:
• randomised controlled trials (RCTs);
• quasi-RCTs;
• non-randomised controlled trials;
• prospective cohort studies;
• retrospective cohort studies;
• cross-sectional studies;
• controlled before-and-aKer studies.
There was no minimum duration for the studies.
Types of participants
Patients without suspected or confirmed COVID-19 infection,
undergoing aerosol-generating procedures (AGPs) and those
healthcare workers (HCWs) treating them.
Setting
• Any healthcare setting.
Types of interventions
Interventions
Any antimicrobial mouthwash and/or nasal spray (alone or in
combination) at any concentration, delivered to the patient or HCW
before and/or aKer an AGP.
Comparator
No treatment or saline or water.
Types of outcome measures
We analysed the following outcomes in the review, but we did not
use them as a basis for including or excluding studies.
We assessed the primary outcomes at a minimum of two weeks. For
all other outcomes, there was no minimum follow-up.
For all outcomes we planned to accept the method of measurement
used by the trialists but we would take a critical approach to the
value of each measure.
Primary outcomes
• Incidence of symptomatic or test-positive COVID-19 infection in
HCWs or patients.
• Significant adverse event: anosmia (or disturbance in sense of
smell).
Secondary outcomes
• COVID-19 viral content of aerosol (when present).
• Change in COVID-19 viral load at site(s) of irrigation.
• Other adverse events: changes in microbiome in oral cavity,
nasal cavity, oro- or nasopharynx.
• Other adverse events: allergy, irritation/burning of nasal, oral
or oropharyngeal mucosa (e.g. erosions, ulcers, bleeding),
long-term staining of mucous membranes or teeth, accidental
ingestion.
Search methods for identification of studies
The Cochrane ENT and Cochrane Oral Health Information
Specialists conducted systematic searches for all human studies.
There were  no language, publication year or publication status
restrictions. We contacted original authors for clarification and
further data when trial reports were  unclear and arranged
translations of papers where possible. The date of the search was
1 June 2020.
Electronic searches
The Information Specialist searched:
• the Cochrane Central Register of Controlled Trials (CENTRAL
2020, Issue 6) (searched via the Cochrane Register of Studies);
• Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-
Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
(1946 to 1 June 2020);
• Ovid EMBASE (1974 to 1 June 2020);
• World Health Organization (WHO) COVID-19 Global literature
on coronavirus disease https://search.bvsalud.org/global-
literature-on-novel-coronavirus-2019-ncov (searched to 1 June
2020);
• Cochrane COVID-19 Study Register https://
covid-19.cochrane.org/ (search via the Cochrane Register of
Studies to 1 June 2020).
The Information Specialists modelled subject strategies for
databases on the search strategy designed for Ovid MEDLINE.
Search strategies for major databases including CENTRAL are
provided in Appendix 1.
Searching other resources
We did  not perform a separate search for adverse eFects. We
planned to consider adverse eFects described in the included
studies only.
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We did not perform a separate search for pre-print publications.
We planned to identify and report as awaiting assessment any we
identified from the sources above that met our inclusion criteria
but we would not extract the data until their publication in a peer-
reviewed journal.
We planned to make eForts to identify full-text papers regardless
of language of publication and to endeavour to seek help with
translation; however, we would not hold up the rapid review
process. Any papers that we were unable to source quickly or were
unable to get translated would be listed as awaiting assessment.
Data collection and analysis
Selection of studies
AMG, HW (and others) performed screening using Covidence.
Two review authors independently screened all titles and abstracts
identified through the searching. Discrepancies were discussed
and, where necessary, a third review author was included. Where
uncertainties remained, we retrieved the full text for clarification.
Two review authors again independently screened the full text of
potentially relevant articles.
We documented and outlined in the final report all decisions
regarding exclusion of studies, taken during screening, with a list of
excluded studies.
Data extraction and management
We planned that AMG, HW (and others) would perform data
extraction using a predefined data extraction form (Word/Excel).
Data were limited to a minimal set of required data items following
input from content experts and methodologists.
A single review author would undertake data extraction and a
second review author would check the completeness/accuracy of
the data extraction. Discrepancies would be discussed and taken to
a third review author as required.
We planned to contact study authors for missing outcome data, or
where there were conflicting data reported across multiple sources
for a single study.
Assessment of risk of bias in included studies
We planned to undertake 'Risk of bias' assessment at the same time
as data extraction. We planned to use the Cochrane RCT 'Risk of
bias' tool and the ROBINS-I tool for non-randomised studies. We
planned to exclude studies judged to be at critical risk of bias from
analysis.
As for data extraction, all judgements were to be checked by a
second review author. Discrepancies would be discussed and taken
to a third review author as required.
Measures of treatment e=ect
We planned to present dichotomous data as risk ratios (RR) with
corresponding 95% confidence intervals (CIs). However, if we
identified case-control studies relevant to the review questions, we
would have considered the use of odds ratio as the appropriate
estimate of eFect.
We planned to present continuous data as a mean diFerence (MD)
with corresponding 95% CIs. Where necessary, we would have
converted outcome data to the same unit of measurement.
Where data were extracted from non-RCTs, we planned to use
adjusted eFects where available. If multiple adjusted eFects were
reported, then we would have chosen the one judged to minimise
the risk of bias due to confounding.
Unit of analysis issues
The unit of analysis was the participant. Any cluster-RCTs would
need to have analysed results taking account of the clustering
present in the data, otherwise we would have used the methods
outlined in Section 16.3.4 of the Cochrane Handbook for Systematic
Reviews of Interventions in order to perform an approximately
correct analysis (Higgins 2011). We planned to include studies with
multiple treatment arms as appropriate, ensuring that there was no
double counting of patients in any meta-analysis.
Dealing with missing data
We planned to contact study authors for missing outcome data.
Where appropriate, we would have used the methods outlined
in Section 7.7.3 of the Cochrane Handbook for Systematic Reviews
of Interventions in order to estimate missing standard deviations
(Higgins 2011). We would not have used any further statistical
methods or carried out any further imputation to account for
missing data.
Assessment of heterogeneity
We planned to assess statistical heterogeneity initially through
inspection of forest plots. We would use the Chi2 for heterogeneity,
with P = 0.10, to indicate substantial heterogeneity (acknowledging
that this has low power if there is a small sample size or few studies).
We also planned to use the I2 statistic, following the interpretation
recommended in the Cochrane Handbook for Systematic Reviews
of Interventions (0% to 40% might not be important; 30% to
60% may represent moderate heterogeneity; 50% to 90% may
represent substantial heterogeneity; 75% to 100% considerable
heterogeneity) (Handbook 2019). We would be cautious in
interpreting the I2 value, as this may be uncertain when there are
few studies.
We planned to explore potential sources of heterogeneity among
study results. Sources may include: clinical setting and clinical
procedure.
Assessment of reporting biases
Where there were 10 or more studies in a meta-analysis, we planned
to assess possible publication bias by visually inspecting a funnel
plot for asymmetry.
Data synthesis
We planned to make a judgement regarding the clinical and
methodological heterogeneity; only where there was deemed to
be reasonable homogeneity across studies would we consider
statistical pooling of data. If appropriate, we would have conducted
statistical pooling of data from RCTs, followed by data from non-
RCTs. We would not have undertaken pooling across diFerent types
of study designs.
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We planned to use a random-eFects model.
Lastly, we planned to undertake a narrative synthesis,
encompassing findings from both RCT and non-RCT studies.
Subgroup analysis and investigation of heterogeneity
Where data were available, we planned to conduct subgroup
analyses, where possible, according to clinical procedure and
clinical setting (e.g. inpatient, outpatient, dental, ENT).
Sensitivity analysis
We planned to undertake sensitivity analysis excluding studies at
high risk of bias.
Summary of findings and assessment of the certainty of the
evidence
We planned to use the GRADE approach and present 'Summary of
findings' tables for all comparisons and all outcomes.
R E S U L T S
Description of studies
Results of the search
The searches retrieved a total of 335  references. This reduced
to 240  aKer the removal of duplicates.  We screened the title
and abstracts of the remaining 240  references. We discarded
206  references and assessed 34  full-text articles.  We identified
four additional duplicates, which we discarded. We excluded all
30 remaining references with reasons recorded in the review (see
Excluded studies).
We did not identify any completed or ongoing studies that met
the inclusion criteria for this review.
The PRISMA diagram in  Figure 1  shows our study search and
selection process.
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Figure 1.   Process for siHing search results and selecting studies for inclusion
 
Included studies
We did not include any studies.
Excluded studies
We excluded 30 papers aKer reviewing the full text. Further details
for the reasons for exclusion can be found in the Characteristics of
excluded studies table. These are the main reasons for exclusion:
We excluded eight  references that were narrative review articles,
which did not report any data of relevance to this review (Carrouel
2020; Dexter 2020; Ham 2020; Hamid 2020; Henwood 2020;
Leboulanger 2020; Parhar 2020).
We also excluded four references as they were letters to the editor
of a journal, providing a comment rather than reporting on a study
(Challacombe 2020; LoKus 2020; Mady 2020; Maguire 2020).
We excluded 18 studies as the intervention was used in an incorrect
population - the trial considered the use of nasal sprays and
gargles  to treat individuals who have the virus, or as routine
prophylaxis for healthcare workers (rather than at the time of
aerosol-generating procedures) (ACTRN12620000470998p; AMPoL
(NCT04409873); BBCovid (NCT04352959); ChiCTR2000030539;
ELVIS-COVID-19 (NCT04382131); GARGLES (NCT04341688);
GARGLESb (NCT04410159); KILLER (NCT04371965); KONS-
COVID-19 (NCT04357990); NCT04344236; NCT04347538;
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NCT04347954; NCT04382040; NCT04408183; NOCOVID
(NCT04337918); PICO (ISRCTN13447477); PIIPPI (NCT04364802);
SINUS WASH (NCT04393792)).
Finally, we excluded one study as it was conducted in an
incorrect population - although participants were infected with a
coronavirus, this was not COVID-19 (Ramalingam 2020).
Risk of bias in included studies
We did not include any studies.
E=ects of interventions
See: Summary of findings 1 Antimicrobial mouthwashes
(gargling) and nasal sprays to protect healthcare workers when
undertaking aerosol-generating procedures (AGPs) on patients
without suspected or confirmed COVID-19 infection
No studies are included in the review. See Summary of findings 1.
D I S C U S S I O N
Summary of main results
We identified no studies for inclusion in this review, nor any ongoing
studies. The absence of completed studies is not surprising given
the relatively recent emergence of COVID-19 infection. However, we
are disappointed that this important clinical question is not being
addressed by ongoing studies.
Overall completeness and applicability of evidence
As no studies are included in the review and the searches
did not identify any relevant ongoing studies, there remains a
lack of evidence regarding the potential benefits or harms of
mouthwashes and nasal sprays when used at the time of AGPs.
Quality of the evidence
We did not include any studies.
Potential biases in the review process
Given the recent emergence of COVID-19 infection, we aimed to
design a protocol that would be inclusive, to encompass as much
relevant information as possible.
The search strategy was designed and run by qualified Cochrane
Information Specialists so any bias here should be minimal. The
search was not limited to the English language. It is possible that
suitable studies have been carried out and the results published
elsewhere in another language; however, we feel that this is
unlikely, as all applicable studies are likely to have been registered
with one of the central trial registries.
All studies that we discarded during our search and selection
process were rejected based on a lack of relevant data (e.g. they
were letter to the editor of a journal, or narrative review articles) or
because they did not address the relevant population.
Agreements and disagreements with other studies or
reviews
We are not aware of any other published reviews that address
the use of antimicrobial mouthwashes and nasal sprays at the time
of AGPs.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
No studies are included in this review, therefore we are unable to
ascertain the relative benefits and harms of the use of antimicrobial
mouthwashes and nasal sprays at the time of aerosol-generating
procedures (AGPs).
Implications for research
We are concerned that no ongoing studies were identified that
address this important question. Evidence regarding the eFicacy
and safety of methods to reduce the risk of COVID-19 transmission
at the time of AGPs is urgently required to ensure that routine
medical and dental procedures may be undertaken without
exposing healthcare professionals to unnecessary risk.
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Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
ACTRN12620000470998p Incorrect population. This trial considers treatment of individuals who are positive for COVID-19,
and is relevant for another review in this suite (Antimicrobial mouthwashes (gargling) and nasal
sprays administered to patients with suspected or confirmed COVID-19 infection to improve pa-
tient outcomes and to protect healthcare workers treating them; Burton 2020b).
AMPoL (NCT04409873) Incorrect population. This trial considers treatment of individuals who are positive for COVID-19,
and is relevant for another review in this suite (Antimicrobial mouthwashes (gargling) and nasal
sprays administered to patients with suspected or confirmed COVID-19 infection to improve pa-
tient outcomes and to protect healthcare workers treating them; Burton 2020b).
BBCovid (NCT04352959) Incorrect population. This trial considers treatment of individuals who are positive for COVID-19,
and is relevant for another review in this suite (Antimicrobial mouthwashes (gargling) and nasal
sprays administered to patients with suspected or confirmed COVID-19 infection to improve pa-
tient outcomes and to protect healthcare workers treating them; Burton 2020b).
Carrouel 2020 Review article, no relevant data. 
Challacombe 2020 Letter to the editor - no relevant data. 
ChiCTR2000030539 Incorrect population. This trial considers treatment of individuals who are positive for COVID-19,
and is relevant for another review in this suite (Antimicrobial mouthwashes (gargling) and nasal
sprays administered to patients with suspected or confirmed COVID-19 infection to improve pa-
tient outcomes and to protect healthcare workers treating them; Burton 2020b).
Dexter 2020 Review article, no relevant data. 
ELVIS-COVID-19
(NCT04382131)
Incorrect population. This trial considers treatment of individuals who are positive for COVID-19,
and is relevant for another review in this suite (Antimicrobial mouthwashes (gargling) and nasal
sprays administered to patients with suspected or confirmed COVID-19 infection to improve pa-
tient outcomes and to protect healthcare workers treating them; Burton 2020b).
GARGLES (NCT04341688) Incorrect population. This trial considers treatment of individuals who are positive for COVID-19,
and is relevant for another review in this suite (Antimicrobial mouthwashes (gargling) and nasal
sprays administered to patients with suspected or confirmed COVID-19 infection to improve pa-
tient outcomes and to protect healthcare workers treating them; Burton 2020b).
GARGLESb (NCT04410159) Incorrect population. This trial considers treatment of individuals who are positive for COVID-19,
and is relevant for another review in this suite (Antimicrobial mouthwashes (gargling) and nasal
sprays administered to patients with suspected or confirmed COVID-19 infection to improve pa-
tient outcomes and to protect healthcare workers treating them; Burton 2020b).
Ham 2020 Review article, no relevant data. 
Hamid 2020 Review article, no relevant data.
Henwood 2020 Review article, no relevant data. 
KILLER (NCT04371965) Incorrect population. This trial considers treatment of individuals who are positive for COVID-19,
and is relevant for another review in this suite (Antimicrobial mouthwashes (gargling) and nasal
sprays administered to patients with suspected or confirmed COVID-19 infection to improve pa-
tient outcomes and to protect healthcare workers treating them; Burton 2020b).
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Study Reason for exclusion
KONS-COVID-19
(NCT04357990)
Incorrect population. This trial considers treatment of individuals who are positive for COVID-19,
and is relevant for another review in this suite (Antimicrobial mouthwashes (gargling) and nasal
sprays administered to patients with suspected or confirmed COVID-19 infection to improve pa-
tient outcomes and to protect healthcare workers treating them; Burton 2020b).
Leboulanger 2020 Review article, no relevant data. 
Loftus 2020 Letter to the editor, no relevant data. 
Mady 2020 Letter to the editor, no relevant data. 
Maguire 2020 Letter to the editor, no relevant data. 
NCT04344236 Incorrect population. This trial considers treatment of individuals who are positive for COVID-19,
and is relevant for another review in this suite (Antimicrobial mouthwashes (gargling) and nasal
sprays administered to patients with suspected or confirmed COVID-19 infection to improve pa-
tient outcomes and to protect healthcare workers treating them; Burton 2020b).
NCT04347538 Incorrect population. This trial considers treatment of individuals who are positive for COVID-19,
and is relevant for another review in this suite (Antimicrobial mouthwashes (gargling) and nasal
sprays administered to patients with suspected or confirmed COVID-19 infection to improve pa-
tient outcomes and to protect healthcare workers treating them; Burton 2020b).
NCT04347954 Incorrect population. This trial considers treatment of individuals who are positive for COVID-19,
and is relevant for another review in this suite (Antimicrobial mouthwashes (gargling) and nasal
sprays administered to patients with suspected or confirmed COVID-19 infection to improve pa-
tient outcomes and to protect healthcare workers treating them; Burton 2020b).
NCT04382040 Incorrect population. This trial considers treatment of individuals who are positive for COVID-19,
and is relevant for another review in this suite (Antimicrobial mouthwashes (gargling) and nasal
sprays administered to patients with suspected or confirmed COVID-19 infection to improve pa-
tient outcomes and to protect healthcare workers treating them; Burton 2020b).
NCT04408183 Incorrect population. This trial considers prophylaxis to prevent acquisition of COVID-19 and is
relevant for another review in this suite (Use of antimicrobial mouthwashes (gargling) and nasal
sprays by healthcare workers to protect them when treating patients with suspected or confirmed
COVID-19 infection; Burton 2020a).
NOCOVID (NCT04337918) Incorrect population. This trial considers treatment of individuals who are positive for COVID-19,
and prophylaxis for healthcare professional during routine clinical care. It is relevant for two other
reviews in this suite (Antimicrobial mouthwashes (gargling) and nasal sprays administered to pa-
tients with suspected or confirmed COVID-19 infection to improve patient outcomes and to protect
healthcare workers treating them; Burton 2020b; and Use of antimicrobial mouthwashes (gargling)
and nasal sprays by healthcare workers to protect them when treating patients with suspected or
confirmed COVID-19 infection; Burton 2020a).
Parhar 2020 Review article, no relevant data. 
PICO (ISRCTN13447477) Incorrect population. This trial considers treatment of individuals who are positive for COVID-19,
and is relevant for another review in this suite (Antimicrobial mouthwashes (gargling) and nasal
sprays administered to patients with suspected or confirmed COVID-19 infection to improve pa-
tient outcomes and to protect healthcare workers treating them; Burton 2020b).
PIIPPI (NCT04364802) Incorrect population. This trial considers prophylaxis to prevent acquisition of COVID-19 and is
relevant for another review in this suite (Use of antimicrobial mouthwashes (gargling) and nasal
sprays by healthcare workers to protect them when treating patients with suspected or confirmed
COVID-19 infection; Burton 2020a).
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Study Reason for exclusion
Ramalingam 2020 Incorrect population - participants did not have COVID-19. 
SINUS WASH (NCT04393792) Incorrect population. This trial considers treatment of individuals who are positive for COVID-19,
and is relevant for another review in this suite (Antimicrobial mouthwashes (gargling) and nasal
sprays administered to patients with suspected or confirmed COVID-19 infection to improve pa-
tient outcomes and to protect healthcare workers treating them; Burton 2020b).
 
 
A P P E N D I C E S
Appendix 1. Search strategies
 
CENTRAL Ovid MEDLINE Ovid Embase
1 ("2019 nCoV" or 2019nCoV or "COVID 19" or
COVID19 or "new coronavirus" or "novel coron-
avirus" or "novel corona virus" or "SARS CoV-2"
or "2019- novel CoV" or ncov19 or ncov-19) AND
CENTRAL:TARGET
2 (Wuhan and (coronavirus or "corona virus"))
AND CENTRAL:TARGET
3 ((coronavirus near3 2019) or ("corona virus"
near3 2019)) AND CENTRAL:TARGET
4 ((wuhan near2 disease) or (wuhan near2 virus))
AND CENTRAL:TARGET
5 ("LAMP assay" or "COVID-19" or "COVID-19
drug treatment" or "COVID-19 diagnostic test-
ing" or "COVID-19 serotherapy" or "COVID-19
vaccine" or "severe acute respiratory syndrome
coronavirus 2" or "spike glycoprotein, COVID-19
virus") AND CENTRAL:TARGET
6 #1 OR #2 OR #3 OR #4 OR #5
7 MESH DESCRIPTOR Mouthwashes EXPLODE
ALL AND CENTRAL:TARGET
8 MESH DESCRIPTOR Nasal Sprays EXPLODE ALL
AND CENTRAL:TARGET
9 MESH DESCRIPTOR Nasal Lavage EXPLODE ALL
AND CENTRAL:TARGET
10 (mouthwash* or gargl* or mouthrins*) AND
CENTRAL:TARGET
11 (oral near3 (spray* or douch* or irrigat* or
lavag* or wash or rins* or decontaminat* or
aerosol or mist or clean*)) AND CENTRAL:TAR-
GET
1 ("2019 nCoV" or 2019nCoV or "COVID 19" or COVID19
or "new coronavirus" or "novel coronavirus" or "novel
corona virus" or "SARS CoV-2" or "2019- novel CoV" or
ncov19 or ncov-19).ab,ti.
2 (Wuhan and (coronavirus or "corona virus")).ab,ti.
3 ((coronavirus or "corona virus") adj3 "2019").ab,ti.
4 (wuhan adj2 (disease or virus)).ab,ti.
5 ("LAMP assay" or "COVID-19" or "COVID-19 drug
treatment" or "COVID-19 diagnostic testing" or "COV-
ID-19 serotherapy" or "COVID-19 vaccine" or "severe
acute respiratory syndrome coronavirus 2" or "spike
glycoprotein, COVID-19 virus").os.
6 1 or 2 or 3 or 4 or 5
7 exp Animals/
8 exp Humans/
9 7 not 8
10 (editorial or comment or letter or newspaper arti-
cle).pt.
11 9 or 10
12 6 not 11
13 exp Mouthwashes/
14 exp Nasal Sprays/
15 exp Nasal Lavage/
16 (mouthwash* or gargl* or mouthrins*).ab,ti.
17 ((oral or mouth or nasal or nose or nasopharyngeal
or larynx* or pharynx* or intranasal) adj3 (spray* or
1. ("2019 nCoV" or
2019nCoV or "COVID
19" or COVID19 or "new
coronavirus" or "novel
coronavirus" or "novel
corona virus" or "SARS
CoV-2" or "2019- nov-
el CoV" or ncov19 or
ncov-19).ab,ti.






4. (wuhan adj2 (disease
or virus)).ab,ti.
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12 (mouth near3 (spray* or douch* or irrigat*
or lavag* or wash or rins* or decontaminat* or
aerosol or mist or clean*)) AND CENTRAL:TAR-
GET
13 (nasal near3 (spray* or douch* or irrigat*
or lavag* or wash or rins* or decontaminat* or
aerosol or mist or clean*)) AND CENTRAL:TAR-
GET
14 (nose near3 (spray* or douch* or irrigat* or
lavag* or wash or rins* or decontaminat* or
aerosol or mist or clean*)) AND CENTRAL:TAR-
GET
15 (nasopharyngeal near3 (spray* or douch* or
irrigat* or lavag* or wash or rins* or deconta-
minat* or aerosol or mist or clean*)) AND CEN-
TRAL:TARGET
16 (larynx* near3 (spray* or douch* or irrigat*
or lavag* or wash or rins* or decontaminat* or
aerosol or mist or clean*)) AND CENTRAL:TAR-
GET
17 (pharynx* near3 (spray* or douch* or irrigat*
or lavag* or wash or rins* or decontaminat* or
aerosol or mist or clean*)) AND CENTRAL:TAR-
GET
18 (intranasal near3 (spray* or douch* or irrigat*
or lavag* or wash or rins* or decontaminat* or
aerosol or mist or clean*)) AND CENTRAL:TAR-
GET
19 MESH DESCRIPTOR Chlorhexidine EXPLODE
ALL AND CENTRAL:TARGET
20 MESH DESCRIPTOR Povidone-Iodine EX-
PLODE ALL AND CENTRAL:TARGET
21 MESH DESCRIPTOR Cetylpyridinium EXPLODE
ALL AND CENTRAL:TARGET
22 MESH DESCRIPTOR Hexetidine EXPLODE ALL
AND CENTRAL:TARGET
23 MESH DESCRIPTOR Anti-Infective Agents, Lo-
cal EXPLODE ALL AND CENTRAL:TARGET
24 MESH DESCRIPTOR Hydrogen Peroxide EX-
PLODE ALL AND CENTRAL:TARGET
25 MESH DESCRIPTOR Carbamide Peroxide EX-
PLODE ALL AND CENTRAL:TARGET
26 MESH DESCRIPTOR Triclosan EXPLODE ALL
AND CENTRAL:TARGET
27 MESH DESCRIPTOR Oils, Volatile EXPLODE
ALL AND CENTRAL:TARGET
28 MESH DESCRIPTOR Plant Oils EXPLODE ALL
AND CENTRAL:TARGET
douch* or irrigat* or lavag* or wash or rins* or decont-





22 exp Anti-Infective Agents, Local/
23 exp Hydrogen Peroxide/
24 exp Carbamide Peroxide/
25 exp Triclosan/
26 exp Oils, volatile/











38 (povidone or chlorhexidine or CHX or PVP or
Polyvinylpyrrolidone or Betadine* or Providine* or
Disadine* or Isodine* or Pharmadine* or Alphadine*
or Betaisodona or Tubulicid or Novalsan or Sebidin or
MK-412A or MK412A).ab,ti.
39 (Chlorhexamed or Corsodyl or Curasept or Dy-
na-Hex or Eludril or Gibitan or Hexidine or Hibiclens or
Hibident or Hibiscrub or Hibisol or Hibitane or Peridex
or avagard).ab,ti.
40 (Hexadecylpyridinium or Cetylpyridium or Biosept
or Ceepryn or Cetamium or Catamium or Sterogenol
or Dobendan or Merocets or Pristacin or Pyrisept or
Angifonil or Cetylyre).ab,ti.
41 (Vagi-Hex or Vagi Hex or VagiHex or Oraldene or
Hexigel or Steri-sol or Steri sol or Hextril or Oraldine or





11. ((oral or mouth or
nasal or nose or na-
sopharyngeal or lar-
ynx* or pharynx* or in-
tranasal) adj3 (spray*
or douch* or irrigat*
or lavag* or wash or
rins* or decontaminat*


























chlorhexidine or CHX or
PVP or Polyvinylpyrroli-
done or Betadine* or
Providine* or Disadine*
or Isodine* or Pharma-
dine* or Alphadine* or
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29 MESH DESCRIPTOR Menthol AND CEN-
TRAL:TARGET
30 MESH DESCRIPTOR Lavandula AND CEN-
TRAL:TARGET
31 MESH DESCRIPTOR Thymus Plant AND CEN-
TRAL:TARGET
32 MESH DESCRIPTOR Mentha piperita AND
CENTRAL:TARGET
33 MESH DESCRIPTOR Cinnamomum zeylan-
icum AND CENTRAL:TARGET
34 MESH DESCRIPTOR Muramidase AND CEN-
TRAL:TARGET
35 MESH DESCRIPTOR Lactoferrin AND CEN-
TRAL:TARGET
36 MESH DESCRIPTOR Glucose Oxidase AND
CENTRAL:TARGET
37 MESH DESCRIPTOR Lactoperoxidase AND
CENTRAL:TARGET
38 (povidone or chlorhexidine or CHX or PVP or
Polyvinylpyrrolidone or Betadine* or Providine*
or Disadine* or Isodine* or Pharmadine* or Al-
phadine* or Betaisodona or Tubulicid or Noval-
san or Sebidin or MK-412A or MK412A) AND CEN-
TRAL:TARGET
39 (Chlorhexamed or Corsodyl or Curasept or
Dyna-Hex or Eludril or Gibitan or Hexidine or
Hibiclens or Hibident or Hibiscrub or Hibisol
or Hibitane or Peridex or avagard) AND CEN-
TRAL:TARGET
40 (Hexadecylpyridinium or Cetylpyridium or
Biosept or Ceepryn or Cetamium or Catami-
um or Sterogenol or Dobendan or Merocets or
Pristacin or Pyrisept or Angifonil or Cetylyre)
AND CENTRAL:TARGET
41 (Vagi-Hex or Vagi Hex or VagiHex or Oraldene
or Hexigel or Steri-sol or Steri sol or Hextril or
Oraldine or Oralspray or Hexoral or Bactidol or
Elsix or Duranil or Doreperol or Hexetidine) AND
CENTRAL:TARGET
42 (Hydrogen Peroxide or H2O2 or Hydroperox-
ide or Superoxol or Oxydol or Perhydrol or Urea
Peroxide or Perhydrol Urea) AND CENTRAL:TAR-
GET
43 (Methyl salicylate or methylsalicylate or
Rheumabal or Metsal Liniment or Hewedolor or
Linsal) AND CENTRAL:TARGET
44 (Tricolsan or Hydroxydiphenyl or
trichlorodiphenyl or Clearasil or Cliniclean or
Irgasan or Trisan or Oxy Skin Wash or pHiso-
42 (Hydrogen Peroxide or H2O2 or Hydroperoxide or
Superoxol or Oxydol or Perhydrol or Urea Peroxide or
Perhydrol Urea).ab,ti.
43 (Methyl salicylate or methylsalicylate or Rheuma-
bal or Metsal Liniment or Hewedolor or Linsal).ab,ti.
44 (Tricolsan or Hydroxydiphenyl or trichlorodiphenyl
or Clearasil or Cliniclean or Irgasan or Trisan or
Oxy Skin Wash or pHisoHex or Sapoderm or Ter-
saseptic or Aquasept or Ster-Zac or Manusept or Mi-
croshield).ab,ti.
45 ((Spray* or douch* or irrigat* or rins* or wash* or
lavag* or intranasal* or topical) adj3 (antimicrobial or
anti-microbial or disinfect* or antisept* or anti- infec-
t*)).ab,ti.
46 ("essential oil$" or "plant oil$" or menthol or men-
thyl or (mint adj2 oil$) or lavender or thyme or pep-
permint or "mentha piperita" or eugenol o eucalyptus
or "blue gum$" or cajeput or clove or cinnamon).ab,ti.
47 (muramidase or lysozyme$ or leftose or lactoferrin
or lactotransferrin or "glucose oxidase" or lactoperox-
idase or "saliva substitute").ab,ti.
48 (Listerine or Biotene).ab,ti.
49 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or
22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31
or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or
41 or 42 or 43 or 44 or 45 or 46 or 47 or 48
50 12 and 49
Betaisodona or Tubuli-
cid or Novalsan or Se-
bidin or MK-412A or
MK412A).ab,ti.
32. (Chlorhexamed or
Corsodyl or Curasept or
Dyna-Hex or Eludril or
Gibitan or Hexidine or
Hibiclens or Hibident or
Hibiscrub or Hibisol or
Hibitane or Peridex or
avagard).ab,ti.
33. (Hexadecylpyridini-
um or Cetylpyridium or
Biosept or Ceepryn or
Cetamium or Catami-
um or Sterogenol or
Dobendan or Merocets
or Pristacin or Pyrisept
or Angifonil or Cety-
lyre).ab,ti.
34. (Vagi-Hex or Va-
gi Hex or VagiHex or
Oraldene or Hexigel or
Steri-sol or Steri sol or
Hextril or Oraldine or
Oralspray or Hexoral
or Bactidol or Elsix or
Duranil or Doreperol or
Hexetidine).ab,ti.
35. (Hydrogen Peroxide
or H2O2 or Hydroperox-
ide or Superoxol or Oxy-








37. ((spray* or douch*
or irrigat* or rins* or




fect* or antisept* or an-
ti- infect*)).ab,ti.




or Irgasan or Trisan or
Oxy Skin Wash or pHiso-
Hex or Sapoderm or
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Hex or Sapoderm or Tersaseptic or Aquasept or
Ster-Zac or Manusept or Microshield) AND CEN-
TRAL:TARGET
45 ((spray* or douch* or irrigat* or rins* or wash*
or lavag* or intranasal* or topical) and (antimi-
crobial or anti-microbial or disinfect* or anti-
sept* or anti-infect*)) AND CENTRAL:TARGET
46 ("essential oil*" or "plant oil*" or menthol
or menthyl or (mint near2 oil*) or lavender or
thyme or peppermint or "mentha piperita" or
eugenol or eucalyptus or "blue gum*" or cajeput
or clove or cinnamon) AND CENTRAL:TARGET
47 (muramidase or lysozyme* or leftose or lacto-
ferrin or lactotransferrin or "glucose oxidase" or
lactoperoxidase or "saliva substitute") AND CEN-
TRAL:TARGET
48 (Listerine or Biotene) AND CENTRAL:TARGET
49 #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13
OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR
#20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26
OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR
#33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39
OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR
#46 OR #47 OR #48
50 #49 AND #6
Tersaseptic or Aquasept
or Ster-Zac or Manusept
or Microshield).ab,ti.
39. ("essential oil$" or
"plant oil$" or men-
thol or menthyl or (mint
adj2 oil$) or lavender or
thyme or peppermint
or "mentha piperita" or
eugenol or eucalyptus
or "blue gum$" or ca-




or lactoferrin or lacto-
transferrin o "glucose
oxidase" or lactoperox-





43. 6 and 42
WHO COVID-19 Register Cochrane COVID-19 Register —
(tw:((oral or mouth or nasal or nose or nasopha-
ryngeal or larynx* or pharynx* or intranasal) ))
AND (tw:(spray* or douch* or irrigat* or lavag*
or wash or rins* or decontaminat* or aerosol or
mist or clean*))
(tw:((mouthwash* or gargl* or mouthrins*)))
(tw:((spray* or douch* or irrigat* or rins* or
wash* or lavag* or intranasal* or topical))) AND
(tw:((antimicrobial or anti-microbial or disin-
fect* or antisept* or anti-infect*)))
(povidone or chlorhexidine or CHX or PVP or
Polyvinylpyrrolidone or Betadine* or Providine*
or Disadine* or Isodine* or Pharmadine* or Al-
phadine* or Betaisodona or Tubulicid or Noval-
san or Sebidin or MK-412A or MK412A)
1 (mouthwash* or gargl* or mouthrins*) AND IN-
REGISTER
2 (oral near3 (spray* or douch* or irrigat* or lavag* or
wash or rins* or decontaminat* or aerosol or mist or
clean*)) AND INREGISTER
3 (mouth near3 (spray* or douch* or irrigat* or lavag*
or wash or rins* or decontaminat* or aerosol or mist
or clean*)) AND INREGISTER
4 (nasal near3 (spray* or douch* or irrigat* or lavag* or
wash or rins* or decontaminat* or aerosol or mist or
clean*)) AND INREGISTER
5 (nose near3 (spray* or douch* or irrigat* or lavag* or
wash or rins* or decontaminat* or aerosol or mist or
clean*)) AND INREGISTER
6 (nasopharyngeal near3 (spray* or douch* or irrigat*
or lavag* or wash or rins* or decontaminat* or aerosol
or mist or clean*)) AND INREGISTER
7 (larynx* near3 (spray* or douch* or irrigat* or lavag*
or wash or rins* or decontaminat* or aerosol or mist
or clean*)) AND INREGISTER
—
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8 (pharynx* near3 (spray* or douch* or irrigat* or
lavag* or wash or rins* or decontaminat* or aerosol or
mist or clean*)) AND INREGISTER
9 (intranasal near3 (spray* or douch* or irrigat* or
lavag* or wash or rins* or decontaminat* or aerosol or
mist or clean*)) AND INREGISTER
10 (povidone or chlorhexidine or CHX or PVP or
Polyvinylpyrrolidone or Betadine* or Providine* or
Disadine* or Isodine* or Pharmadine* or Alphadine*
or Betaisodona or Tubulicid or Novalsan or Sebidin or
MK-412A or MK412A) AND INREGISTER
11 (Chlorhexamed or Corsodyl or Curasept or Dy-
na-Hex or Eludril or Gibitan or Hexidine or Hibiclens or
Hibident or Hibiscrub or Hibisol or Hibitane or Peridex
or avagard) AND INREGISTER
12 (Hexadecylpyridinium or Cetylpyridium or Biosept
or Ceepryn or Cetamium or Catamium or Sterogenol
or Dobendan or Merocets or Pristacin or Pyrisept or
Angifonil or Cetylyre) AND INREGISTER
13 (Vagi-Hex or Vagi Hex or VagiHex or Oraldene or
Hexigel or Steri-sol or Steri sol or Hextril or Oraldine or
Oralspray or Hexoral or Bactidol or Elsix or Duranil or
Doreperol or Hexetidine) AND INREGISTER
14 (Hydrogen Peroxide or H2O2 or Hydroperoxide or
Superoxol or Oxydol or Perhydrol or Urea Peroxide or
Perhydrol Urea) AND INREGISTER
15 (Methyl salicylate or methylsalicylate or Rheuma-
bal or Metsal Liniment or Hewedolor or Linsal) AND
INREGISTER
16 (Tricolsan or Hydroxydiphenyl or trichlorodiphenyl
or Clearasil or Cliniclean or Irgasan or Trisan or Oxy
Skin Wash or pHisoHex or Sapoderm or Tersaseptic or
Aquasept or Ster-Zac or Manusept or Microshield) AND
INREGISTER
17 ((Spray* or douch* or irrigat* or rins* or wash* or
lavag* or intranasal* or topical) and (antimicrobial
or anti-microbial or disinfect* or antisept* or anti in-
fect*)) AND INREGISTER
18 ("essential oil*" or "plant oil*" or menthol or men-
thyl or (mint near2 oil*) or lavender or thyme or pep-
permint or "mentha piperita" or eugenol or eucalyp-
tus or "blue gum*" or cajeput or clove or cinnamon)
AND INREGISTER
19 (muramidase or lysozyme* or leftose or lactoferrin
or lactotransferrin or "glucose oxidase" or lactoperox-
idase or "saliva substitute") AND INREGISTER
20 (Listerine or Biotene) AND INREGISTER
21 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR
#9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR
#16 OR #17 OR #18 OR #19 OR #20
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